(Q36716637)

15 August 2017

1 reference

title

Enoximone. A review of its pharmacological properties and therapeutic potential (English)

1 reference

15 August 2017

3

Brogden RN

1 reference

15 August 2017

Vernon MW

1

1 reference

PubMed ID

1724645

15 August 2017

Heel RC

series ordinal

2

1 reference

15 August 2017

1 December 1991

1 reference

15 August 2017

1 reference

15 August 2017

42

1 reference

15 August 2017

6

1 reference

15 August 2017

997-1017

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199142060-00008

15 August 2017

0 references

cites work

Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure

1 reference

12 December 2020

Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism

1 reference

12 December 2020

Influence of phosphodiesterase inhibition on myocardial energetics in dilative cardiomyopathy

1 reference

12 December 2020

[Effect of oral long-term enoximone therapy on the arrhythmia profile in chronic heart failure]

1 reference

12 December 2020

Long-term oral enoximone therapy in chronic cardiac failure

1 reference

12 December 2020

Overview of cardiovascular physiologic and pharmacologic aspects of selective phosphodiesterase peak III inhibitors

1 reference

12 December 2020

Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance

1 reference

12 December 2020

Diastolic function in patients with severe heart failure: comparison of the effects of enoximone and nitroprusside

1 reference

12 December 2020

Double-blind crossover comparison of enoximone and placebo in patients with congestive heart failure

1 reference

12 December 2020

A comparison of hemodynamic effects of one-month oral captopril and enoximone treatment for severe congestive heart failure

1 reference

12 December 2020

Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow

1 reference

12 December 2020

Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite

1 reference

12 December 2020

Oral enoximone pharmacokinetics in patients with congestive heart failure

1 reference

12 December 2020

Differential hemodynamic effects of oral enoximone in severe congestive heart failure

1 reference

12 December 2020

Disposition Kinetics of Orally Administered Enoximone in Patients with Moderate to Severe Heart Failure

1 reference

12 December 2020

Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy

1 reference

12 December 2020

Electrophysiological effects of intravenous MDL 17.043

1 reference

12 December 2020

Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study.

1 reference

12 December 2020

Lack of effect of enoximone on the pharmacokinetics of digoxin in patients with congestive heart failure

1 reference

12 December 2020

Kinetics of fenoximone, a new cardiotonic, in healthy subjects

1 reference

12 December 2020

The influence of various degrees of cardiac failure, chronic medical treatment, and acute additional enoximone application on the parameters of the vasopressor system

1 reference

12 December 2020

Recent advances in the management of chronic heart failure

1 reference

12 December 2020

Regulation of force and intracellular calcium transients by cyclic AMP generated by forskolin, MDL 17,043 and isoprenaline, and its modulation by muscarinic receptor agents: a novel mechanism for accentuated antagonism

1 reference

12 December 2020

Intravenous and oral MDL 17043 (A new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patients

1 reference

12 December 2020

Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity

1 reference

12 December 2020

Enoximone as a bridge to heart transplantation: the Utah experience

1 reference

12 December 2020

Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure

1 reference

12 December 2020

The effects of enoximone on renal function in patients with congestive heart failure

1 reference

12 December 2020

Pharmacology of enoximone

1 reference

12 December 2020

Enoximone as pharmacologic "bridging" to heart transplantation

1 reference

12 December 2020

Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure

1 reference

12 December 2020

MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure.

1 reference

12 December 2020

Comparison of dobutamine and enoximone for low output states following cardiac surgery

1 reference

12 December 2020

The electrophysiologic effects of enoximone in patients with preexisting ventricular tachyarrhythmias

1 reference

12 December 2020

Long-term enoximone therapy in unstable chronic heart failure

1 reference

12 December 2020

Effects of low dose enoximone for chronic congestive heart failure

1 reference

12 December 2020

Effects of enoximone in patients with heart failure uncontrolled by captopril and diuretics

1 reference

12 December 2020

Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group

1 reference

12 December 2020

Enoximone as alternative to mechanical support while awaiting cardiac transplantation

1 reference

12 December 2020

Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure

1 reference

12 December 2020

Human serum and plasma protein binding of enoximone and its sulfoxide metabolite

1 reference

12 December 2020

Renal and hormonal effects of phosphodiesterase III inhibition in congestive heart failure

1 reference

12 December 2020

Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of newer inotropic agents

1 reference

12 December 2020

Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1.3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one).

1 reference

12 December 2020

Effects of enoximone on quality of life

1 reference

12 December 2020

Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure

1 reference

12 December 2020

Clinical pharmacology of intravenous enoximone: Pharmacodynamics and pharmacokinetics in patients with heart failure

1 reference

12 December 2020

Characterization of the Cardiovascular Activities of a New Cardiotonic Agent, MDL 17043 (1,3-Dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one)

1 reference

12 December 2020

Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement

1 reference

12 December 2020

A preliminary report of the effects of orally administered enoximone on regional hemodynamics in congestive heart failure.

1 reference

12 December 2020

Application of a frequency definition of ventricular proarrhythmia

1 reference

12 December 2020

MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response

1 reference

12 December 2020

Hemodynamic effects of MDL 17,043, a new cardiotonic agent, in patients with congestive heart failure: comparison with sodium nitroprusside

1 reference

12 December 2020

Cardiac energetics after intravenous enoximone in idiopathic dilated cardiomyopathy

1 reference

12 December 2020

Pharmacokinetics of intravenous enoximone in dialysis patients

1 reference

12 December 2020

LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum.

1 reference

12 December 2020

Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group

1 reference

12 December 2020

Studies aimed at elucidating the mechanism of action of CI-914, a new cardiotonic agent.

1 reference

12 December 2020

Enoximone and ventricular arrhythmia in chronic heart failure

1 reference

12 December 2020

Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs

1 reference

12 December 2020

Disparity between improvement in left ventricular function and changes in clinical status and exercise capacity during chronic enoximone therapy

1 reference

12 December 2020

Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone

1 reference

12 December 2020

Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesterase

1 reference

12 December 2020

Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure

1 reference

12 December 2020

Hemodynamic effects of prolonged intravenous therapy with enoximone in patients with severe congestive heart failure

1 reference

12 December 2020

Is phosphodiesterase inhibition arrhythmogenic? Electrophysiologic effects in pithed rats and in normoxic and hypoxic rabbit atria of enoximone, a new cardiotonic agent

1 reference

12 December 2020

A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure

1 reference

12 December 2020

Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure

1 reference

12 December 2020

Enoximone improves selection of candidates for urgent cardiac transplantation

1 reference

12 December 2020

[Enoximone and the therapeutic strategy in patients awaiting emergency cardiac graft]

1 reference

12 December 2020

Differential effects of sulmazole (AR-L 115 BS) on contractile force and cyclic AMP levels in canine ventricular muscle: comparison with MDL 17,043

1 reference

12 December 2020

Potential mechanisms of improved left ventricular function with enoximone in severe congestive heart failure.

1 reference

12 December 2020

Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure

1 reference

12 December 2020

Placebo-controlled trial of oral enoximone in end-stage congestive heart failure refractory to optimal treatment

1 reference

12 December 2020

The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure

1 reference

12 December 2020

10.2165/00003495-199142060-00008

Identifiers

DOI

1 reference

PubMed ID

1724645

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

1724645